IN THE CLAIMS

COMPLETE LISTING OF ALL CLAIMS, WITH MARKINGS AND STATUS IDENTIFIERS

In the revised claim set appearing below, currently amended claims have deletions shown by ~~strikethrough~~ or brackets [[ ]], and additions shown by underlining. This listing of claims will replace all prior versions and listings of the claims in the application.

Listing of Claims:

1. (canceled)

2. (currently amended) The method ~~A peptide~~ according to claim [[1]] 6 or 9, wherein said peptide of formula (I) is a peptide wherein

A^1 is L-Phe, D-Phe, L-Cpa or D-Cpa;

A^3 is L-Tyr, L-Trp or L-3-Pal;

A^4 is D-Trp;

A^6 is β-Ala or Gaba;

A^7 is L-Cys;

A^8 is L-Thr, L-Trp, L-Leu or L-Nal; and

R^2 and R^3 are each H;

or a pharmaceutically acceptable salt thereof.

3. (currently amended) The method ~~A peptide~~ according to claim [[2]] 6 or 9, wherein said peptide is of the formula

Cpa-cyclo(D-Cys-3-Pal-D-Trp-Lys-Gaba-Cys)-Nal-NH_2;

Cpa-cyclo(D-Cys-3-Pal-D-Trp-Lys-β-Ala-Cys)-Nal-NH_2;

Phe-cyclo(D-Cys-3-Pal-D-Trp-Lys-Gaba-Cys)-Nal-NH_2;

Phe-cyclo(D-Cys-Tyr-D-Trp-Lys-Gaba-Cys)-Nal-NH_2;

Phe-cyclo(D-Cys-Trp-D-Trp-Lys-Gaba-Cys)-Nal-NH_2;

Phe-cyclo(D-Cys-Tyr-D-Trp-Lys-Gaba-Cys)-Trp-NH_2;

D-Phe-cyclo(D-Cys-Tyr-D-Trp-Lys-Gaba-Cys)-Nal-NH_2;

D-Phe-cyclo(D-Cys-Tyr-D-Trp-Lys-Gaba-Cys)-Leu-NH_2; or

Phe-cyclo-(D-Cys-Tyr-D-Trp-Lys-Gaba-Cys)-Thr-NH_2;

or a pharmaceutically acceptable salt thereof.

4. (currently amended) The method ~~A peptide~~ according to claim [[3]] 6 or 9, wherein said peptide is of the formula

Cpa-cyclo(D-Cys-3-Pal-D-Trp-Lys-Gaba-Cys)-Nal-NH_2; or

Cpa-cyclo(D-Cys-3-Pal-D-Trp-Lys-β-Ala-Cys)-Nal-NH_2;

or a pharmaceutically acceptable salt thereof.

5. (currently amended) [[A]] The method according to claim 6 or 9, wherein said peptide or pharmaceutically acceptable salt thereof is in the form of a pharmaceutical composition ~~useful for eliciting a somatostatin agonist response in a human or other animal~~ which comprises an effective amount of a peptide of formula (I) ~~according to claim 1~~ or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

6. (previously presented) A method of eliciting a somatostatin agonist response in a human or other animal in need thereof, which comprises administering an effective amount of a peptide of formula (I)

X-A^1-cyclo(D-Cys-A^3-A^4-Lys-A^6-A^7)-A^8-Y,

(I)

or a pharmaceutically acceptable salt thereof,

wherein

X is H,  or  ;

A^1 and A^3 are each independently the D- or L-isomer of an amino acid selected from the group consisting of Phe, Tyr, Tyr(I), Trp, 3-Pal, 4-Pal, Cpa and Nal;

A^4 is L-Trp, D-Trp, L-ß-methyl-Trp or D-ß-methyl-Trp;

A^6 is -NH-$(CHR^1)_n$-CO-, where n is 2, 3, or 4;

A^7 is L- or D-Cys;

A^8 is the D- or L-isomer of an amino acid selected from the group consisting of Phe, Tyr, Tyr(I), Trp, Nal, Cpa, Val, Leu, Ile, Ser and Thr;

Y is NR^2R^3 where R^2 and R^3 are each independently H or $(C_1\text{-}C_5)$alkyl;

R^1 is selected from the group consisting H, $(C_1\text{-}C_4)$alkyl and $-CH_2$-aryl; wherein said aryl is an optionally substituted moiety selected from the group consisting of phenyl, 1-naphthyl, and 2-naphthyl, wherein said optionally substituted moiety is optionally substituted with one or more substituents each independently selected from the group consisting of $(C_{1\text{-}6})$alkyl, $(C_{2\text{-}6})$alkenyl, $(C_{2\text{-}6})$alkynyl, aryl, aryl$(C_{1\text{-}6})$alkyl, $(C_{1\text{-}6})$alkoxy, $-N(R^4R^5)$, -COOH, $-CON(R^4R^5)$, halo, -OH, -CN, and $-NO_2$;

R^4 and R^5 each is, independently for each occurrence, H or $(C_{1\text{-}3})$alkyl;

where the Cys of A^2 is bonded to the Cys of A^7 by a di-sulfide bond formed from the thiol groups of each Cys,

to the human or other animal.

7. (canceled)

8. (canceled)

9. (currently amended) A method of inhibiting the secretion of growth hormone, insulin, glucagon or pancreatic exocrine secretion in a human or other animal in need thereof, which comprises administering a peptide of formula (I)

$$X\text{-}A^1\text{-cyclo(D-Cys-}A^3\text{-}A^4\text{-Lys-}A^6\text{-}A^7\text{)-}A^8\text{-Y},$$

(I)

or a pharmaceutically acceptable salt thereof,

wherein

X is H,  or  ;

A^1 and A^3 are each independently the D- or L-isomer of an amino acid selected from the group consisting of Phe, Tyr, Tyr(I), Trp, 3-Pal, 4-Pal, Cpa and Nal;

A^4 is L-Trp, D-Trp, L-ß-methyl-Trp or D-ß-methyl-Trp;

A^6 is $-NH\text{-}(CHR^1)_n\text{-}CO-$, where n is 2, 3, or 4;

A^7 is L- or D-Cys;

A^8 is the D- or L-isomer of an amino acid selected from the group consisting of Phe, Tyr, Tyr(I), Trp, Nal, Cpa, Val, Leu, Ile, Ser and Thr;

Y is NR^2R^3 where R^2 and R^3 are each independently H or $(C_1\text{-}C_5)$alkyl;

R^1 is selected from the group consisting H, $(C_1\text{-}C_4)$alkyl and $-CH_2$-aryl; wherein said aryl is an optionally substituted moiety selected from the group consisting of phenyl, 1-naphthyl, and 2-naphthyl, wherein said optionally substituted moiety is optionally substituted with one or more substituents each independently selected from the group consisting of $(C_{1\text{-}6})$alkyl, $(C_{2\text{-}6})$alkenyl, $(C_{2\text{-}6})$alkynyl, aryl, aryl$(C_{1\text{-}6})$alkyl, $(C_{1\text{-}6})$alkoxy, $-N(R^4R^5)$, -COOH, $-CON(R^4R^5)$, halo, -OH, -CN, and $-NO_2$;

R^4 and R^5 each is, independently for each occurrence, H or $(C_{1\text{-}3})$alkyl;

where the Cys of A^2 is bonded to the Cys of A^7 by a di-sulfide bond formed from the thiol groups of each Cys,

to said human or other animal.

10. (canceled)

11. (canceled)